Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aimed to investigate the effectiveness of CoronaVac vaccine, which is more than 90% protective in healthy people, in cancer patients receiving active chemotherapy. In this study, to collect information to measure the amount of antibodies produced by the vaccine in the blood of volunteers with the CoronoVac vaccine and to compare it with healthy volunteers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Breast or lung cancer patients receiving active chemotherapy and 2 doses of CoronaVac vaccine |
| ||
| Healthy volunteers who received two doses of coronavac vaccine |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CoronoVAC | Biological | SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination |
|
| Measure | Description | Time Frame |
|---|---|---|
| Antibody levels above the defined cut-off | SARS-CoV-2 IgG II ≥ 50.0 AU/ml (positive) and SARSCoV- 2 IgM >1 (positive) | Between the third and sixth weeks after the second dose of vaccine |
Not provided
Not provided
Inclusion Criteria:
Group 1
Group 2
Exclusion Criteria:
For all groups
Not provided
Not provided
Breast or lung cancer patients receiving active chemotherapy and healthy volunteers
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Erdoğan Selçuk Şeber, Asoc.prof | Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji | Study Chair |
| Halil Taşkaynatan, Asoc.prof | İzmir Özel Ege Şehir Hastanesi | Principal Investigator |
| Özkan Alan, MD | Tekirdağ Dr. İsmail Fehmi Cumalıoğlu Şehir Hastanesi | Principal Investigator |
| Üyesi Sonat Pınar Kara, MD | Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi İç Hastalıkları ABD, İç Hastalıkları | Principal Investigator |
| Aliye Çelikkol, MD | Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi Tıbbi Biyokimya ABD, | Principal Investigator |
| Okan Avcı, MD | Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji | Principal Investigator |
| Eyyüp Çavdar, MD | Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji | Principal Investigator |
| Kubilay Karaboyun, MD | Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tekirdağ Namık Kemal ÜNiversitesi | Tekirdağ | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
blood samples
| Berna Erdal, DR | Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi Mikrobiyoloji ABD | Principal Investigator |
| Yakup İriağaç, MD | Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji | Study Director |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided